Abstract
The effectiveness of transplacental drug therapy for prenatally diagnosed isolated congenital complete atrioventricular block (CCAVB) is controversial. Nine cases of prenatal isolated CCAVB were treated from 2002 to 2007. Ritodrine was administered transplacentally to all fetuses and betamethasone to those whose mothers tested positive for maternal anti-SSA/Ro antibodies. Six of the nine patients had an anti-SSA/Ro-positive mother and received transplacental betamethasone 4 mg/day at a median gestational age of 28 weeks (range, 24–31 weeks). No patients exhibited an improvement in the degrees of complete heart block, and one patient died in utero. No serious adverse events occurred. After the mean follow-up period of 1.7 ± 1.3 years, all five patients treated with transplacental betamethasone experienced a good cardiac function, whereas one of the three patients not treated with transplacental betamethasone experienced cardiomyopathy and died at the age of 4 months. Pacemaker implantation was required for seven of the eight live-born infants. Transplacental betamethasone therapy for the patients with isolated CCAVB neither improved the degree of atrioventricular block nor decreased the rate of patients requiring pacemaker implantation, but it probably reduced the risk for the development of myocardial disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barclay CS, French MAH, Ross LD, Sokol RJ (1987) Successful pregnancy following steroid therapy and plasma exchange in a woman with anti-Ro (SS-A) antibodies: case report. Br J Obstet Gynaecol 94:369–371
Brucato A, Frassi M, Franceschini F et al (2001) Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 44:1832–1835
Brucato A, Astori MG, Cimaz R et al (2006) Normal neuropsychological development in children with congenital complete heart block who may or may not be exposed to high-dose dexamethasone in utero. Ann Rheum Dis 65:1422–1426
Buyon JP, Hiebert R, Copel J et al (1998) Autoimmune-associated congenital heart block: demographics, mortality, morbidity, and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 31:1658–1666
Carpenter RJ, Strasburger JF, Garson A et al (1986) Fetal ventricular pacing for hydrops secondary to complete atrioventricular block. J Am Coll Cardiol 8:1434–1436
Costedoat-Chalumeau N, Amoura Z, Hong DLT et al (2003) Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis 62:1010–1012
Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM et al (2004) Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum 50:3187–3194
Deloof E, Devlieger H, Van Hoestenberghe R, Vandenberghe K, Daenen W, Gewllig M (1996) Management with a staged approach of the premature hydropic fetus due to complete congenital heart block. Eur J Pediatr 156:521–523
Friedman DM, Kim MY, Copel JA et al (2008) Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR interval and dexamethasone evaluation (PRIDE) prospective study. Circulation 117:485–493
Gladman G, Silverman ED, Yuk-Law et al (2002) Fetal echocardiographic screening of pregnancies of mothers with anti-Ro and/or anti-La antibodies. Am J Perinatol 19:73–80
Grove AMM, Allan LD, Rosenthal E (1996) Outcome of isolated congenital complete heart block diagnosed in utero. Heart 75:190–194
Hornberger LK, Sahn DJ (2007) Rhythm abnormalities of the fetus. Heart 93:1294–1300
Jaeggi ET, Hamilton RM, Silverman ED et al (2002) Outcome of children with fetal, neonatal, or childhood diagnosis of isolated congenital atrioventricular block. J Am Coll Cardiol 39:130–137
Jaeggi ET, Fouron JC, Silverman ED et al (2004) Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 110:1542–1548
Kurosaki K, Miyazaki A, Watanabe K, Echigo S (2008) Long-term outcome of isolated congenital complete atrioventricular block pacing since neonatal period: experience at a single Japanese institution. Circ J 72:81–87
Lee BH, Stoll BJ, McDonald SA, Higgins RD (2008) Neurodevelopmental outcomes of extremely low-birth-weight infants exposed prenatally to dexamethasone versus betamethasone. Pediatrics 121:289–296
Maeno Y, Himeno W, Saito A et al (2005) Clinical course of fetal congenital atrioventricular block in the Japanese population: a multicentre experience. Heart 91:1075–1079
Michaelsson M, Engle MA (1972) Congenital complete heart block: an international study of the natural history story. Clin Cardiol 4:86–101
Saleeb S, Copel J, Friedman D, Buyon JP (1999) Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum 42:2335–2345
Villain E, Coastedoat-Chalumeau N, Marijon E, Boudjemline Y, Piette JC, Bonnet D (2006) Presentation and prognosis of complete atrioventricular block in childhood, according to maternal antibody status. J Am Coll Cardiol 48:1682–1687
Weindling SN, Saul JP, Triedman JK et al (1994) Staged pacing therapy for congenital complete heart block in premature infants. Am J Cardiol 74:412–413
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hayashi, T., Kaneko, M., Kim, KS. et al. Outcome of Prenatally Diagnosed Isolated Congenital Complete Atrioventricular Block Treated with Transplacental Betamethasone or Ritodrine Therapy. Pediatr Cardiol 30, 35–40 (2009). https://doi.org/10.1007/s00246-008-9273-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-008-9273-5